Purpose-built for physicians
CHICAGO — Adults with type 2 diabetes may have lower risk for fractures if they use semaglutide compared with other medications, according to data presented at ENDO 2026.
As Healio previously reported, a retrospective cohort study found that semaglutide (Ozempic/Wegovy, Novo Nordisk) was associated with a 26% lower risk for fractures than sleeve gastrectomy for people with obesity. Sun H. Kim, MS, MD, associate professor of medicine at Stanford University Medical Center and senior author on the previous study, said researchers thought the reduced risk for fracture with semaglutide may have been tied to greater weight loss in the sleeve gastrectomy group.
“The things that we wanted to evaluate was whether [lower risk for fracture] was unique to semaglutide or whether it was related to the differential in weight loss,” Kim said during a presentation. “Our primary objective was to compare fracture incidence among adults with type 2 diabetes treated with semaglutide or another GLP-1 or other FDA-approved medications for weight loss.”
Kim and colleagues conducted a retrospective cohort study of adults aged at least 18 years with type 2 diabetes in the Atropos Health Eos electronic health record database. Adults were considered to have used a medication if they initiated it within 1 year of diabetes diagnosis and had a second mention of medication use or refill at 9 to 15 months. Researchers compared fracture incidence between adults using semaglutide and those receiving comparator drugs, which included dulaglutide (Trulicity, Eli Lilly), phentermine/topiramate (Qsymia, Vivus) and naltrexone/bupropion (Contrave, Currax Pharmaceuticals).
